Piper Sandler Expands European Healthcare Investment Banking with the Hiring of Vincenzo di Nicola
Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Vincenzo di Nicola as a managing director within the firm’s healthcare investment banking group. He will expand the firm’s European healthcare team and the global pharma outsourcing coverage, and will be based in the firm’s London office.
Prior to joining the firm, di Nicola was a managing director, head of healthcare Europe and co-head of pharma outsourcing at Cantor Fitzgerald. Prior to that, he was a managing director and head of healthcare Europe at Robert W. Baird & Co.
“We are excited to welcome Vincenzo to our healthcare platform,” said Peter Day, co-head of healthcare investment banking at Piper Sandler. “With 20 years of investment banking experience predominantly focused on healthcare, we look forward to leveraging Vincenzo’s deep industry expertise as we expand our European healthcare investment banking platform as well as strengthen our global pharma outsourcing coverage.”
Di Nicola earned a bachelor’s degree in international economics from the University of Naples and a Masters in Finance from the London Business School.
ABOUT PIPER SANDLER
Piper Sandler Companies (NYSE: PIPR) is a leading investment bank driven to help clients Realize the Power of Partnership®. Securities brokerage and investment banking services are offered in the U.S. through Piper Sandler & Co., member SIPC and NYSE; in Europe through Piper Sandler Ltd., authorized and regulated by the U.K. Financial Conduct Authority; and in Hong Kong through Piper Sandler Hong Kong Limited, authorized and regulated by the Securities and Futures Commission. Private equity strategies and fixed income advisory services are offered through separately registered advisory affiliates.
Follow Piper Sandler: LinkedIn | Facebook | Twitter
©2021. Since 1895. Piper Sandler Companies. 800 Nicollet Mall, Minneapolis, Minnesota 55402-7036
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128006143/en/
Contact information
Pamela Steensland
Tel: 612 303-8185
pamela.steensland@psc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 09:00:00 EET | Press release
Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leading cause of business loss, the need for advanced security measures continues to grow. “Launching Vonage Silent Authentication API for the U.S. customers marks a tra
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 08:30:00 EET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 08:00:00 EET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator treatments at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The company will also showcase its leadership in community education through a number of events including two symposia, a live anatomy workshop, multiple masterclasses and meet-the-expert sessions, and a booth that will delve into the science behind its innovations. “With ten posters spanning all key aesthetic treatment modalities and areas across the face and body, our data at IMCAS truly showcases the breadth and versatility of our injectable aesthetics portfolio and how we continue to drive innovation with our trusted products. In tandem with our first-class Galderma Aesthetic Injector Network (GAIN) educational activities, conducted in partnership with renowned experts, we are equ
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLD Symposium™ 202622.1.2026 08:00:00 EET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study with oral nizubaglustat for late-infantile/juvenile GM2 and Niemann-Pick Type C diseases (RAINBOW) on February 5, presenting preliminary clinical efficacy and safety data. The data underscore nizubaglustat’s potential as a therapeutic option, reinforcing Azafaros’ commitment to addressing critical unmet needs in lysosomal storage disorders. Nizubaglustat reinstates pro-neuronal transcriptional programs in human CLN3 retinal organoidson February 6 (Rapid Fire
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom